Summary
This Mendelian randomization study investigated whether the cardiovascular benefit of lowering LDL-cholesterol depends on the mechanism of lowering. Using genetic variants in CETP and HMGCR genes as natural experiments, the authors found that CETP variants—which raise HDL-C and lower LDL-C concordantly—were associated with reduced cardiovascular risk in a magnitude similar to statin-induced LDL-C reduction. The findings suggest that LDL-C reduction achieved through different biological pathways may have comparable clinical benefit, informing drug development and lipid management strategies.
UK applicability
The findings are relevant to United Kingdom cardiovascular medicine and lipid management practice, as they inform the interpretation of cholesterol-lowering interventions and support evidence-based prescribing of statins. However, the study involved primarily North American and United Kingdom cohorts, so results are directly applicable to UK populations.
Key measures
Odds ratios for major cardiovascular events; changes in HDL-C, LDL-C, and apolipoprotein B levels; CETP and HMGCR genetic scores
Outcomes reported
The study examined the association between genetic variants in the CETP and HMGCR genes, changes in lipoprotein levels (HDL-C, LDL-C, apoB), and risk of major cardiovascular events across 102,837 participants in the primary analysis and 189,539 in validation cohorts.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.